Good news is coming. The list of outstanding Chinese herbal medicine stocks has been released.

According to the Ministry of Commerce on April 27th, the Ministry of Commerce and five other departments are organizing the pilot project for the consumption of traditional Chinese medicine services, and have identified 18 regions as pilot areas for the integration of traditional Chinese medicine services consumption and service trade development. Huaxiang Securities pointed out that policies continue to be the core factor affecting the Chinese herbal medicine industry in 2026. The Chinese herbal medicine industry may continue to show structural differentiation based on core competitiveness. According to Securities Times Data Bao statistics, as of April 28th, 36 Chinese herbal medicine stocks have already released reports related to their first quarter performance in 2026. Among them, 16 stocks have profits exceeding 1 billion yuan, with Guangdong Baiyunshan, CR Sanjiu temporarily ranking first and second, with net profits of 1.784 billion yuan and 1.076 billion yuan respectively; Dong-E-E-Jiao, Yiling Pharmaceutical, Jichuan Pharmaceutical, Tasly, and Buchang Pharma closely follow, with net profits all exceeding 300 million yuan. In terms of changes in net profit, among the 16 Chinese herbal medicine stocks with profits exceeding 1 billion yuan, 6 stocks have a net profit increase of more than 10% in the first quarter.